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INTRODUCTION Alzheimer’s disease (AD) is the most common form of dementia. It is characterized by a progressive memory loss and changes in behaviour due
to the neuronal death in several regions of central nervous system (CNS), mainly the cerebral cortex, the hippocampus and the amygdala. Although the major
hallmarks of AD are plaques of amyloid-β peptides (Aβ) and neurofibrillary tangles (NFT) of hyperphosphorylated Tau protein, the aetiology of the disease remains
unknown. Among others, it has been reported that the immune system plays an important role in both protective and pathological processes in AD and microglial
cells would be the main responsible.
OBJECTIVES As previously indicated, microglial cells are involved in AD. Nevertheless, the influence of these cells has not been completely elucidated. The main
goal of the present work is to understand the role of microglia in the progression of AD and to review the use of monoclonal antibodies (Mabs) in order to reduce
Aβ burden.
IMPLICATIONS OF MICROGLIA RECEPTORS IN AD
Several microglia receptors cooperate in the recognition, internalization and
removal of Aβ and polymorphisms in some of them may result in protection
or damage [1].
In some cases microglia receptors may increase Aβ uptake:
But in other may mediate early synapse loss:
Fig 1. Mechanisms of clearance of amyloid-β. From Nat Rev Neurosci. 2015 
Jun;16(6):358-72.
MICROGLIA IS INVOLVED IN Tau PROPAGATION
Although abnormal Tau protein has been found in different regions of the
brain, specially the entorhinal cortex (EC) and the hippocampus, how it has
been propagated was unknown. It had been proposed that microglia could play
an important role in Tau propagation due to their ability to phagocyte and
exocyte several molecules and it has been confirmed recently [2].
Fig 3. (A) Colocalization of Tau (green, AT8+) with microglia (red, Iba1+) in the
hippocampus of PS19 mouse brain. (B) PLX3397-treated animals showed a reduction of
microglia in EC and hippocampus. (C) Treated mice showed 47% and 70% reductions of
Tau in EC and hippocampus. (D) Exosomal fraction of ATP- and LPS-treated microglia but
not neurons or astrocytes contains Tau. (E) Neurons treated with this exosomal fraction
contain Tau. From Nat Neurosci. 2015 Nov;18(11):1584-93.
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MICROGLIA IN AGING
Microglia may be protective or harmful depending on its phenotype. It has
been reported that aging enhances classical activation of microglia and
mitigate the neuroprotective alternative phenotype [3].
Fig 4. Hypothetical spectrum of microglial phenotypes. It stands out
that in AD patients ROS generation is increased and phagocytic
ability is reduced. From Glia. 2016 Apr 21. doi: 10.1002/glia.22988.
ANTIBODIES AS A NEW APPROACH TO FIGHT AGAINST AD
The use of antibodies against Aβ is supported by several evidences which
demonstrate that FcR-mediated phagocytosis contribute in the plaques
clearance. However, due to over-activation of microglia some of them lead to
plasma leakage. That is why several studies with lack Fc domain antibodies are
in development. In fact, experiments in the triple transgenic mice (3xTg-AD)
which were treated with scFv-h3D6 (derived from bapineuzumab) show an
improvement in cognition and a neuroprotective effect in deep cerebellar
nuclei [4].
Fig 5. Number of neurons in the
three deep cerebellar nuclei. Black,
NTg untreated animal; Striped, NTg
scFv treated; White, 3xTgAD
untreated; Squared, 3xTgAD scFv
treated. From Mabs. 2013 Sep-
Oct;5(5):660-4.
CONCLUSIONS (I) Physiological bases of AD remain unknown, (II) microglia plays a central role in the development of the disease, (III) this role may be
pathological or protective depending on several circumstances such as aging and microglia phenotype among other, (IV) immunotherapy may be a good
pharmacological approach to solve Aβ accumulation and (V) it is of vital importance to continue with the studies to establish the role of microglia and how it can be
modulated to find new therapeutic targets.
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Fig 2. Aβ oligomers induce
synapse loss in mice (black).
However, co-injection of Aβ
oligomers with antibody
against C1q (striped) have not
effect. From Science. 2016 May
6;352(6286):712-6.
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